JP2009543866A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543866A5
JP2009543866A5 JP2009520778A JP2009520778A JP2009543866A5 JP 2009543866 A5 JP2009543866 A5 JP 2009543866A5 JP 2009520778 A JP2009520778 A JP 2009520778A JP 2009520778 A JP2009520778 A JP 2009520778A JP 2009543866 A5 JP2009543866 A5 JP 2009543866A5
Authority
JP
Japan
Prior art keywords
weight
amount
pharmaceutical
formulation
foamy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009520778A
Other languages
English (en)
Other versions
JP2009543866A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016029 external-priority patent/WO2008010963A2/en
Publication of JP2009543866A publication Critical patent/JP2009543866A/ja
Publication of JP2009543866A5 publication Critical patent/JP2009543866A5/ja
Pending legal-status Critical Current

Links

Claims (39)

  1. 治療上有効量のイミキモドと脂肪酸とを含む、泡状医薬製剤。
  2. イミキモドが、前記製剤の全質量に基づき少なくとも1質量%の量で存在する、請求項1記載の泡状医薬製剤。
  3. イミキモドが、前記製剤の全質量に基づき少なくとも3質量%の量で存在する、請求項1記載の泡状医薬製剤。
  4. イミキモドが、前記製剤の全質量に基づき少なくとも5質量%の量で存在する、請求項1記載の泡状医薬製剤。
  5. イミキモドが、前記製剤の全質量に基づき最大6質量%の量で存在する、請求項1記載の泡状医薬製剤。
  6. 脂肪酸が、前記製剤の全質量に基づき少なくとも5質量%の量で存在する、請求項1〜5のいずれか1項記載の泡状医薬製剤。
  7. 脂肪酸が、前記製剤の全質量に基づき少なくとも20質量%の量で存在する、請求項1〜6のいずれか1項記載の泡状医薬製剤。
  8. 脂肪酸が、前記製剤の全質量に基づき最大30質量%の量で存在する、請求項1〜7のいずれか1項記載の泡状医薬製剤。
  9. 脂肪酸がイソステアリン酸、オレイン酸およびそれらの混合物からなる群より選択される、請求項1〜8のいずれか1項記載の泡状医薬製剤。
  10. 脂肪酸がイソステアリン酸である、請求項9記載の泡状医薬製剤。
  11. 噴霧剤をさらに含む、請求項1〜10のいずれか1項記載の泡状医薬製剤。
  12. 噴霧剤が、前記製剤の全質量に基づき少なくとも5質量%の量で存在する、請求項11記載の泡状医薬製剤。
  13. 噴霧剤が、前記製剤の全質量に基づき少なくとも10質量%の量で存在する、請求項11記載の泡状医薬製剤。
  14. 噴霧剤が、前記製剤の全質量に基づき少なくとも15質量%の量で存在する、請求項11記載の泡状医薬製剤。
  15. 噴霧剤が炭化水素である、請求項11〜14のいずれか1項記載の泡状医薬製剤。
  16. 炭化水素がプロパン、ブタンおよびそれらの混合物からなる群より選択される、請求項15記載の泡状医薬製剤。
  17. 水をさらに含む、請求項1〜16のいずれか1項記載の泡状医薬製剤。
  18. 防腐系をさらに含む、請求項1〜17のいずれか1項記載の泡状医薬製剤。
  19. 防腐系が、前記製剤の全質量に基づき少なくとも0.1質量%の量で存在する、請求項18記載の泡状医薬製剤。
  20. 防腐系が、前記製剤の全質量に基づき最大3質量%の量で存在する、請求項17記載の泡状医薬製剤。
  21. 防腐系がメチルパラベン、プロピルパラベン、ベンジルアルコールまたはそれらの混合物を含む、請求項18〜20のいずれか1項記載の泡状医薬製剤。
  22. 乳化剤をさらに含む、請求項1〜21のいずれか1項記載の泡状医薬製剤。
  23. 乳化剤が、前記製剤の全質量に基づき少なくとも0.5質量%の量で存在する、請求項22記載の泡状医薬製剤。
  24. 乳化剤が、前記製剤の全質量に基づき最大5質量%の量で存在する、請求項22記載の泡状医薬製剤。
  25. 乳化剤がポリソルベート60、ソルビタンモノステアレートおよびそれらの混合物からなる群より選択される、請求項22〜24のいずれか1項記載の泡状医薬製剤。
  26. 粘度増強剤をさらに含む、請求項1〜25のいずれか1項記載の泡状医薬製剤。
  27. 粘度増強剤が、前記製剤の全質量に基づき少なくとも0.5質量%の量で存在する、請求項26記載の泡状医薬製剤。
  28. 粘度増強剤が、前記製剤の全質量に基づき少なくとも1質量%の量で存在する、請求項26記載の泡状医薬製剤。
  29. 粘度増強剤が、前記製剤の全質量に基づき最大6質量%の量で存在する、請求項26記載の泡状医薬製剤。
  30. 粘度増強剤がセチルアルコール、ステアリルアルコール、キタンサンガムおよびそれらの混合物からなる群より選択される、請求項26〜29のいずれか1項記載の泡状医薬製剤。
  31. 皮膚軟化剤をさらに含む、請求項1〜30のいずれか1項記載の泡状医薬製剤。
  32. 湿潤剤をさらに含む、請求項1〜31のいずれか1項記載の泡状医薬製剤。
  33. 前記製剤が水中油型乳剤である、請求項17〜32のいずれか1項記載の泡状医薬製剤。
  34. エーロゾルバイアル内に封入された請求項1〜33のいずれか1項記載の製剤を含む、包装製剤。
  35. エーロゾルバイアルが絞り弁を備えている、請求項34記載の包装製剤。
  36. 光線性角化症を治療するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物
  37. 基底細胞癌を治療するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物
  38. 肛門生殖器疣贅を治療するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物
  39. インターフェロンの生合成を誘導するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物
JP2009520778A 2006-07-18 2007-07-12 免疫応答修飾製剤 Pending JP2009543866A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80766906P 2006-07-18 2006-07-18
PCT/US2007/016029 WO2008010963A2 (en) 2006-07-18 2007-07-12 Immune response modifier formulations

Publications (2)

Publication Number Publication Date
JP2009543866A JP2009543866A (ja) 2009-12-10
JP2009543866A5 true JP2009543866A5 (ja) 2010-09-02

Family

ID=38828444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009520778A Pending JP2009543866A (ja) 2006-07-18 2007-07-12 免疫応答修飾製剤

Country Status (16)

Country Link
US (1) US20100092401A1 (ja)
EP (1) EP1889609B1 (ja)
JP (1) JP2009543866A (ja)
AR (1) AR062000A1 (ja)
AU (1) AU2007275815A1 (ja)
CA (1) CA2658031C (ja)
CL (1) CL2007002095A1 (ja)
IL (1) IL184563A (ja)
ME (1) MEP18208A (ja)
NO (1) NO343857B1 (ja)
RS (1) RS54276B1 (ja)
RU (1) RU2481108C2 (ja)
UA (1) UA96124C2 (ja)
UY (1) UY30495A1 (ja)
WO (1) WO2008010963A2 (ja)
ZA (1) ZA200901084B (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
WO2004037225A2 (en) 2002-10-25 2004-05-06 Foamix Ltd. Cosmetic and pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
CN101175493A (zh) 2005-03-14 2008-05-07 3M创新有限公司 治疗光化性角化病的方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8501734B2 (en) 2008-05-26 2013-08-06 Oncotyrol-Center For Personalized Cancer Medicine Gmbh (Ltd.) Medical intervention in haematological cancers
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
SI2378876T1 (sl) 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
AU2010237596A1 (en) 2009-04-01 2011-10-27 Wirra Ip Pty Ltd A multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
AU2010274097B2 (en) 2009-07-13 2016-06-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
EP2584900B1 (en) * 2010-06-25 2019-01-02 Medicis Pharmaceutical Corporation Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
KR101962658B1 (ko) * 2010-11-04 2019-07-31 442 벤쳐스 엘엘씨 피부 상태를 치료하기 위한 조성물 및 방법
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
KR101996538B1 (ko) * 2017-02-13 2019-07-04 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US24906A (en) * 1859-07-26 Simeon goodfellow
US3700674A (en) * 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
US4013665A (en) * 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4052393A (en) * 1975-11-03 1977-10-04 E. R. Squibb & Sons, Inc. 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters
US4191767A (en) * 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4197403A (en) * 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
CA2156408C (en) * 1993-03-17 2005-02-15 Daniel C. Duan Aerosol formulation containing a polyester dispersing aid
DE69737935T2 (de) * 1996-10-25 2008-04-03 Minnesota Mining And Manufacturing Co., St. Paul Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
SI1040112T1 (en) * 1997-12-11 2005-02-28 Minnesota Mining And Manufacturing Company Imidazonaphthyridines and their use in inducing cytokine biosynthesis
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2002534377A (ja) * 1999-01-08 2002-10-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節因子を用いて粘膜関連の病態を治療するための製剤および方法
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
DE19941509A1 (de) * 1999-08-31 2001-03-29 Interconnectron Ges Fuer Ind S Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen
JP4394775B2 (ja) * 1999-09-03 2010-01-06 株式会社ダイゾー 油中水型泡状エアゾール組成物およびその製造方法
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
WO2003080114A2 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinoline adjuvants for vaccines
US9668972B2 (en) * 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
BRPI0408476A (pt) * 2003-03-13 2006-04-04 3M Innovative Properties Co métodos para melhorar a qualidade da pele
US7186416B2 (en) * 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
AU2004268665A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
EP2046121B1 (en) * 2006-07-14 2012-08-22 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam

Similar Documents

Publication Publication Date Title
JP2009543866A5 (ja)
JP4684404B2 (ja) 消炎鎮痛外用剤組成物
ES2391563T5 (es) Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor
ES2555258T3 (es) Profármacos de opioides administrables por vía transdérmica, composiciones que no inducen al abuso y procedimientos de uso de los profármacos opioides
JP6794420B2 (ja) 外用医薬組成物
BRPI0509708B8 (pt) espuma farmacêutica, composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbídeo e/ou triglicerídeos de cadeia média e uso
RS54276B1 (en) FOAM FORMULATIONS AS IMMUNE RESPONSE MODIFIERS
JP2008502664A (ja) カルシトリオールとプロピオン酸クロベタゾールとの組合せ、アルコール相、少なくとも1種の揮発性シリコーン、および1種の不揮発性油性相を含むスプレー組成物
TW200815045A (en) Pharmaceutical compositions of ropinirole and methods of use thereof
JP2008513467A5 (ja)
RS54824B1 (sr) Topikalna formulacija za inhibiciju jak-a
UA124181C2 (uk) Знеболююча композиція місцевої дії
WO2010050889A1 (en) Topical composition comprising a combination of at least two penetration enhancing agents
WO2006100489A2 (en) A transdermal topical composition and its uses
US20110092438A1 (en) Composition for external application comprising transcription factor decoy as active ingredient
EP3677265A1 (en) Composition for preventing or treating sleep disorders
TW202017566A (zh) 醫藥組成物及減量抑制方法
JP4585104B2 (ja) 外用消炎鎮痛剤医薬組成物
ES2861052T3 (es) Composición tópica que comprende oxibutinina para el tratamiento de la hiperhidrosis
TWI716394B (zh) 外用醫藥組合物
JP5019724B2 (ja) 抗真菌医薬組成物
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
JP2022163191A (ja) 直腸フォーム製剤
JP6512599B2 (ja) 外用医薬組成物